Claims
- 1. A dosage in the form of a tablet comprising: a drug layer comprising 35 wt % morphine sulfate, 58.5 wt % polyethylene oxide possessing a 200,000 molecular weight, 6 wt % polyvinylpyrrolidone, 0.45 wt % magnesium stearate, and 0.05 wt % butylated hydroxytoluene which drug layer weighs 86 mg; a displacement-push layer comprising 93.67 wt % polyethylene oxide of 7,000,000 molecular weight, 5 wt % hydroxypropylmethylcellulose, 1 wt % ferric oxide, 0.25 wt % magnesium stearate, and 0.083 wt % butylated hydroxytoluene which displacement push layer weighs 55 mg; a semipermeable wall surrounding the layer; and a passageway on the semipermeable wall.
- 2. The dosage in the form of a tablet according to claim 1, wherein the drug layer weighs 172 mg and the displacement-push layer weighs 91 mg.
- 3. The dosage in the form of a tablet according to claim 1, wherein the drug layer weighs 287 mg and the displacement-push layer weighs 151 mg.
- 4. The dosage in the form of a tablet according to claim 1 wherein the polyethylene oxide in the drug layer possesses a 300,000 molecular weight.
- 5. A dosage in the form of a tablet comprising: a drug composition comprising 35 wt % morphine sulfate, 58.5 wt % polyethylene oxide possessing a 200,000 molecular weight, 6 wt % polyvinylpyrrolidone, 0.45 wt % magnesium stearate and 0.05 wt % butylated hydroxytoluene; a push composition comprising 63.675 wt % polyethylene oxide comprising a 7,000,000 molecular weight, 30 wt % sodium chloride, 5 wt % hydroxypropylcellulose, 1 wt % ferric oxide and 0.075 wt % butylated hydroxytoluene; a semipermeable wall that surrounds the compositions; and, a passageway in the wall.
- 6. The dosage in the form of a tablet according to claim 5, wherein the drug composition weighs at least one of 86 mg, 172 mg, and 287 mg.
- 7. The dosage in the form of a tablet according to claim 5, wherein the push composition weighs at least one of 55 mg, 91 mg, and 151 mg.
- 8. The dosage in the form of a tablet according to claim 5, wherein the polyethylene oxide in the drug composition comprises a 300,000 molecular weight.
Parent Case Info
This application is a continuation, of application Ser. No. 08/449,620, filed May 24, 1995, now U.S. Pat. No. 5,593,695, which application Ser. No. 08/449,620 is a division of U.S. patent application Ser. No. 08/266,075, filed Jun. 27, 1994, and now U.S. Pat. No. 5,460,826, and benefit of the filing date of said earlier filed application is claimed under 35 USC .sctn. 120.
US Referenced Citations (16)
Foreign Referenced Citations (1)
Number |
Date |
Country |
0377518 |
Jun 1989 |
EPX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
266075 |
Jun 1994 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
449620 |
May 1995 |
|